Abstract:
Objective
To evaluate the efficacy of neoadjuvant immunotherapy combined with chemotherapy and targeted therapy in patients with stage ⅢA lung adenocarcinoma， as well as the feasibility and safety of thoracoscopic minimally invasive surgery.
Methods
A retrospective analysis was conducted on a case of thoracoscopic right lower lobectomy performed in Apr. 2024 at the First Medical Center of the PLA General Hospital. The patient had stage ⅢA lung adenocarcinoma with confirmed pathological response following neoadjuvant chemotherapy， immunotherapy， and targeted therapy.
Results
The surgical procedure was successfully completed， albeit with considerable difficulty. The operation lasted 150 minutes with an estimated blood loss of 50 ml. Postoperative recovery was uneventful， with no complications such as air leakage or atelectasis. The patient was discharged in good condition on postoperative day 5.
Conclusion
Patients with stage ⅢA lung adenocarcinoma harboring EGFR-sensitive mutations demonstrated a clear pathological response following neoadjuvant chemotherapy combined with immunotherapy and targeted therapy. Thoracoscopic surgery is safe and feasible in this context.
Key words:
Lobectomy,
Lung cancer,
Neoadjuvant therapy
Yiming Liu, Jiaxin Wen, Kai Zhao, Zhiqiang Xue. Thoracoscopic right middle and lower lobe resection after neoadjuvant treatment for stage ⅢA lung a denocarcinoma[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(05): 311-313.